research use only
Cat.No.S3497
|
In vitro |
Water : 100 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 604.71 | Formula | C18H31GdN4O9 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 138071-82-6 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Gadovist, Gadavist,ZK 135079 | SMILES | [Gd+3].OCC(O)C(CO)N1CCN(CCN(CCN(CC1)CC([O-])=O)CC([O-])=O)CC([O-])=O | ||
Read more about storage stability stock solution CAS number SMILES
| References |
|---|
(data from https://clinicaltrials.gov, updated on 2026-01-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04373564 | RECRUITING | Motor Function; Cognitive Function; Contrast Media |
Guerbet |
2021-03-24 | PHASE4 |
| NCT02156739 | ACTIVE_NOT_RECRUITING | Hepatocellular Carcinoma; Liver and Intrahepatic Bile Duct Disorder; Metastatic Malignant Neoplasm in the Liver; Primary Malignant Liver Neoplasm |
M.D. Anderson Cancer Center |
2014-10-13 | |
| NCT07796360 | NOT_YET_RECRUITING | Healthy Volunteers |
National Institute of Neurological Disorders and Stroke (NINDS) |
2026-09-14 | PHASE1 |
| NCT04369560 | RECRUITING | Urinary Bladder Neoplasms |
Jodi Maranchie |
2025-05-23 | EARLY_PHASE1 |
| NCT07472491 | RECRUITING | Known or Highly Suspected Central Nervous System (CNS) Lesion; Known or Highly Suspected Body (Excluding CNS) Lesion |
GE Healthcare |
2026-04-01 | PHASE2; PHASE3 |
| NCT04219904 | ACTIVE_NOT_RECRUITING | Stage IA Cervical Cancer; Stage IA1 Cervical Cancer; Stage IA2 Cervical Cancer; Stage IB Cervical Cancer; Stage IB1 Cervical Cancer; Stage IB2 Cervical Cancer; Stage IB3 Cervical Cancer |
M.D. Anderson Cancer Center |
2018-09-07 | EARLY_PHASE1 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.